Physician attitudes towards pharmacological cognitive enhancement: Safety concerns are paramount

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Banjo, Opeyemi C ^a   Nadler, Roland ^a   Reiner, Peter B ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE; MODAFINIL; NOOTROPIC AGENT; SILDENAFIL; BENZHYDRYL DERIVATIVE; CENTRAL STIMULANT AGENT; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANADA; COGNITION; CONTROLLED STUDY; DRUG CHOICE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; FEMALE; HUMAN; MALE; MEDICAL PRACTICE; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIMARY MEDICAL CARE; UNITED STATES; UNSPECIFIED SIDE EFFECT; URBAN AREA; ATTITUDE TO HEALTH; CLINICAL PRACTICE; COGNITIVE DEFECT; DRUG EFFECT; DRUG THERAPY; DRUG UTILIZATION; MIDDLE AGED; PHYSICIAN; PSYCHOLOGICAL ASPECT; SAFETY; STANDARD;

ADULT; AGED; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; COGNITION; COGNITION DISORDERS; DRUG THERAPY; DRUG UTILIZATION; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; METHYLPHENIDATE; MIDDLE AGED; NOOTROPIC AGENTS; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS; PIPERAZINES; PURINES; SAFETY; SULFONES;

EID: 78650774200     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014322     Document Type: Article

References (46)

1. Bostrom N (2005) In defense of posthuman dignity. Bioethics 3: 202-214.
2. Fukuyama F (2002) Our posthuman future: consequences of the biotechnology revolution. New York: Farrar, Straus and Giroux. 256 p.
3. President's Council on Bioethics (2003) Beyond therapy: biotechnology and the pursuit of happiness. New York: Dana Press. 400 p.
4. Hunt E (1995) The role of intelligence in modern society. American Scientist 83: 356-367.
5. Brooks D (2008) The cognitive age. The New York Times, 2008 2 May. Available: http://www.nytimes.com/2008/05/02/opinion/02brooks.html. Accessed 2010 4 June.
6. Caplan A, Elliott C (2004) Is it ethical to use enhancement technologies to make us better than well? PLoS Med 3: 172-175.
7. Whitehouse PJ, Juengst E, Mehlman M, Murray TH (1997) Enhancing cognition in the intellectually intact. Hastings Cent Rep 3: 14-22.
8. Rose SP (2002) 'Smart drugs': Do they work? Are they ethical? Will they be legal? Nat Rev Neurosci 12: 975-979.
9. Farah MJ, Illes J, Cook-Deegan R, Gardner H, Kandel ER, et al. (2004) Neurocognitive enhancement: What can we do and what should we do? Nat Rev Neurosci 5: 421-425.
10. Chatterjee A (2004) Cosmetic neurology: The controversy over enhancing movement, mentation, and mood. Neurology 6: 968-974.
11. Schulz K (2006) Brave neuro world. The Nation 2: 11-16.
12. Turner DC, Sahakian BJ (2006) Neuroethics of cognitive enhancement. BioSocieties 1: 113-123.
13. Hyman S (2006) Improving our brains? BioSocieties 1: 103-111.
14. Bush SS (2006) Neurocognitive enhancement: Ethical considerations for an emerging subspecialty. Appl Neuropsychol 2: 125-136.
15. Sarewitz D, Karas TH (2006) Policy implications of technologies for cognitive enhancement. Consortium for Science, Policy, and Outcomes, Arizona State University. 32p. Available: http://www.cspo.org/documents/FinalEnhancedCognitionReport.pdf. Accessed 2010 4 June.
16. Garreau J (2006) A dose of genius. Washington Post, 2006 11 June. Available: http://www.washingtonpost.com/wp-dyn/content/article/2006/06/10/AR2006061001181.html. Accessed 2010 4 June.
17. Hughes J (2007) The struggle for smarter world. Futures, 8: 942-954.
18. British Medical Association (2007) Boosting your brainpower: ethical aspects of cognitive enhancements. A discussion paper from the British Medical Association. 39p. Available: http://www.bma.org.uk/images/Boosting_brainpower_tcm41-147266.pdf. Accessed 2010 4 June.
19. Young M (2008) Kickstart my heart. n+1 7: 209-213.
20. Persson I, Savulescu J (2008) The perils of cognitive enhancement and the urgent imperative to enhance the moral character of humanity. Journal of Applied Philosophy 3: 162-177.
21. Greely H, Sahakian B, Harris J, Kessler RC, Gazzaniga M, et al. (2008) Towards responsible use of cognitive-enhancing drugs by the healthy. Nature 7223: 702-705.
22. Schneider S (2008) Future minds: Transhumanism, cognitive enhancement and the nature of persons. In: Ravitsky V, Fiester A, Caplan AL, eds. The Penn Center Guide to Bioethics. New York: Springer. pp 95-110.
23. Racine E, Forlini C (2009) Expectations regarding cognitive enhancement create substantial challenges. J Med Ethics 8: 469-470.
24. Bostrom N, Roache R (in press) Smart policy: Cognitive enhancement and the public interest. In: Savulescu J, Muelen R, Kahane G, eds. Enhancing Human Capabilities. Oxford: Wiley-Blackwell.
25. Cakic V (2009) Smart drugs for cognitive enhancement: Ethical and pragmatic considerations in the era of cosmetic neurology. J Med Ethics 10: 611-615.
26. Cascio J (2009) Get smarter. Atlantic Monthly 304: 94-100.
27. Scripko PD (2010) Enhancement's place in medicine. J Med Ethics 5: 293-296.
28. Bergstrom LS, Lynoe N (2008) Enhancing concentration, mood and memory in healthy individuals: An empirical study of attitudes among general practitioners and the general population. Scand J Public Health 5: 532-537.
29. Larriviere D, Williams MA, Rizzo M, Bonnie RJ, the AAN Ethics, Law and Humanities Committee (2009) Responding to requests from adult patients for neuroenhancements: Guidance of the ethics, law and humanities committee. Neurology 17: 1406-1412.
30. Ravelingien A, Braeckman J, Crevits L, De Ridder D, Mortier E (2009) 'Cosmetic neurology' and the moral complicity argument. Neuroethics 3: 151-162.
31. Synofzik M (2009) Ethically justified, clinically applicable criteria for physician decision-making in psychopharmacological enhancement. Neuroethics 2: 89-102.
32. Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, et al. (2006) Mild cognitive impairment. Lancet 9518: 1262-1270.
33. Crook T, Bartus RT, Ferris SH, Whitehouse P, Cohen GD, et al. (1986) Ageassociated memory impairment: Proposed diagnostic criteria and measures of clinical change-report of a national institute of mental health work group. Developmental Neuropsychology 4: 261-276.
34. Larrabee GJ, Crook TH (1994) Estimated prevalence of age-associated memory impairment derived from standardized tests of memory function. Int Psychogeriatr 6: 95-104.
35. Koivisto K, Reinikainen KJ, Hanninen T, Vanhanen M, Helkala EL, et al. (1995) Prevalence of age-associated memory impairment in a randomly selected population from eastern Finland. Neurology 4: 741-747.
36. Chatterjee A (2007) Cosmetic neurology and cosmetic surgery: Parallels, predictions, and challenges. Cambridge Quart Healthcare Ethics 2: 129-137.
37. Savulescu J (2006) Justice, fairness, and enhancement. Ann N Y Acad Sci 1093: 321-338.
38. Daniels N (2000) Normal functioning and the treatment-enhancement distinction. Cambridge Quart Healthcare Ethics 3: 309-322.
39. Wiesing U (2008) The history of medical enhancement: From restitutio ad integrum to transformatio ad optimum? Medical Enhancement and Posthumanity 2: 9-24.
40. Pieters T, Snelders S (2009) Psychotropic drug use: Between healing and enhancing the mind. Neuroethics 2: 63-73.
41. Flower R (2004) Lifestyle drugs: Pharmacology and the social agenda. Trends Pharmacol Sci 4: 182-185.
42. Metzl JM, Herzig RM (2007) Medicalisation in the 21st century: Introduction. Lancet 9562: 697-698.
43. Poitras G, Meredith L (2008) Ethical transparency and economic medicalization. Journal of Business Ethics 3: 313-325.
44. Reiner PB (2010) Distinguishing between restoration and enhancement in neuropharmacology. Virtual Mentor 12: 885-888.
45. Busch C, De Maret PS, Flynn T, Kellum R, Le S, et al. (2010) Content analysis. Available: http://writing.colostate.edu/guides/research/content/.Accessed 2010 15 February.
46. Freelon D (2010) ReCal Software. Available: http://dfreelon.org/utils/recalfront/. Accessed 2010 3 March.